Montana–based ETS Wound Care has been awarded FDA clearance for its Mirragen advanced wound matrix for treatment of acute and chronic wounds.
The device consists of a fully resorbable borate glass matrix comprised of fibers and beads.
Mirragen is designed to be packed into wounds to control wound fluids.
The company plans to make the device commercially available via a controlled domestic market release in early second quarter of 2017 and to release it to the broader domestic market in 2018. — Cynthia Jessup